Forty-seven recipients of first renal transplant with non-HLA-identical living donors received sirolimus ( SRL ) , tacrolimus ( TAC ) , and ST without induction therapy and were randomized to undergo ST ( TAC/SRL group , n = 24 ) or TAC ( SRL/ST group , n = 21 ) withdrawal 3 months after transplantation .
